Combined Effects of Nutritional and Exercise Countermeasures
This study has been completed.
Sponsor:
University of Arkansas
Information provided by:
University of Arkansas
ClinicalTrials.gov Identifier:
NCT00447044
First received: March 12, 2007
Last updated: June 17, 2009
Last verified: June 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to see if a combination of resistance exercises and amino acid capsules can reduce muscle loss and maintain muscle function during bedrest. This experiment will imitate many of the physical conditions experienced by astronauts during space flight by examining the effects of resistance exercise or nutrition on muscle during 2 days of bedrest. The diet of astronauts will also be imitated by providing diets in the General Clinic Research Center.
| Condition | Intervention |
|---|---|
|
Muscular Atrophy Muscle Weakness |
Behavioral: Resistance Exercise Dietary Supplement: diet orange soda Dietary Supplement: essential amino acids |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Diagnostic |
| Official Title: | Combined Effects of Nutritional and Exercise Countermeasures |
Resource links provided by NLM:
MedlinePlus related topics:
Exercise and Physical Fitness
Drug Information available for:
Amino acids
U.S. FDA Resources
Further study details as provided by University of Arkansas:
Primary Outcome Measures:
- Fractional synthetic rate of muscle growth. [ Time Frame: two days. ] [ Designated as safety issue: No ]
| Enrollment: | 31 |
| Study Start Date: | January 2007 |
| Study Completion Date: | June 2009 |
| Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 2
Subjects drink essential amino acid supplement 3x day for 2 days.
|
Dietary Supplement: essential amino acids
Subjects drink 15 grams of EAA mixed into diet orange soda 3x day for 2 days.
|
|
Placebo Comparator: 1
Subjects receive inert substance versus protein supplement.
|
Dietary Supplement: diet orange soda
Subjects drink diet orange soda 3x day for 2 days.
|
|
Experimental: 3
Resistance exercise.
|
Behavioral: Resistance Exercise
Subjects will lift weights with their legs.
|
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- 18-50 years of age
- Availability of transport and ability to report to Research Center at appointed times
Exclusion Criteria:
- Subjects with limiting or unstable angina or a cardiology confirmed ECG which demonstrates cardiac abnormalities such as > 0.2 mV horizontal or downsloping ST segment depression, frequent arrhythmia's (>10 PVC/min), or valvular disease.
- Subjects with vascular disease as determined by a combination of risk factors of peripheral atherosclerosis, namely hypertension, obesity, diabetes, hypercholesterolemia and/or evidence of venous or arterial insufficiency upon palpitation of femoral, popliteal, and pedal arteries.
- Any history of hypo- or hyper-coagulation disorders including subjects taking Coumadin or with a history of DVT or PE at any point in their lifetime.
- Any subject that has a chronically elevated systolic pressure >170 or a diastolic blood pressure > 100 will be excluded. Subjects may be included if they are taking blood pressure medication and have a blood pressure below these criteria.
- Any subject with an uncontrolled metabolic disease including liver or renal disease.
- Fasting blood glucose of >126 mg/dl on two separate occasions
- Presence of acute illness or metabolically unstable chronic illness.
- Any subject currently on weight-loss diet.
- Inability to abstain from smoking for duration of study.
- Recent ingestion of anabolic steroids (within 6 months).
- Subjects with atrial fibrillation, history of syncope, angina or congestive heart failure.
- Subjects with a recently (6 months) treated cancer other than Basal Cell Carcinoma.
- Pregnancy/lactation.
- Any other condition or event considered exclusionary by the PI and covering faculty
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00447044
Locations
| United States, Arkansas | |
| University of Arkansas for Medical Sciences | |
| Little Rock, Arkansas, United States, 72205 | |
Sponsors and Collaborators
University of Arkansas
Investigators
| Principal Investigator: | Arny Ferrando, PhD | University of Arkansas |
More Information
No publications provided
| Responsible Party: | Arny A. Ferrando, PhD, UAMS |
| ClinicalTrials.gov Identifier: | NCT00447044 History of Changes |
| Other Study ID Numbers: | 72779 |
| Study First Received: | March 12, 2007 |
| Last Updated: | June 17, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Arkansas:
|
Muscle loss and Maintenance of Muscle function |
Additional relevant MeSH terms:
|
Asthenia Muscular Atrophy Muscle Weakness Paresis Atrophy Signs and Symptoms Neuromuscular Manifestations |
Neurologic Manifestations Nervous System Diseases Pathological Conditions, Anatomical Muscular Diseases Musculoskeletal Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on May 19, 2013